53MO Nal-IRI and 5-FU/LV compared to 5-FU/LV in patients with cholangio- and gallbladder carcinoma previously treated with gemcitabine-based therapies (NALIRICC – AIO-HEP-0116)

作者：A. Vogel, P. Wenzel, G. Folprecht, P. Schütt, H. Wege, A. Kretzschmar, L. Jacobasch, N. Ziegenhagen, S. Boeck, S. Kanzler, J. Mohm, S. Belle, Daniel Pink, T.O. Götze, E. Goekkurt, U. Graeven, M. Schaaf, M. Kirstein, A. Saborowski · 发表于：Annals of Oncology · 年份：2022 · DOI：10.1016/j.annonc.2022.07.081 · 被引用次数：33 · 研究领域：Cholangiocarcinoma and Gallbladder Cancer Studies、Peptidase Inhibition and Analysis、Gallbladder and Bile Duct Disorders